News

Results   1-10 of 28

Bio-Signal Group is ISO 13485 certified

October, 2015

Bio-Signal Group is now accredited to ISO 13485 for the design and manufacture of EEG instruments and electrodes

Diagnostic accuracy of microEEG®: A miniature, wireless EEG device

April, 2014

Diagnostic accuracy of microEEG®: A miniature, wireless EEG device: The results of a prospective clinical trial of microEEG® to measure its sensitivity and specificity compared to a “reference” EEG machine were published in the journal of Epilepsy and Behavior (link to full paper). The EEG recordings were acquired from Emergency Department (ED) patients with AMS, a population where the advantages of microEEG® are particularly valuable. Using the unblinded interpretation (abnormal or normal) of EEGs recorded from the reference system as a gold standard, the measured sensitivity and specificity of EEGs obtained from the microEEG® system did not differ significantly in either measurement condition including the use of unconventional electrodes with microEEG®. Thus, the diagnostic accuracy of microEEG® is comparable to that of the reference system in this clinical ED setting. View Manuscript

 

Effect of microEEG® on Clinical Management and Outcomes of Emergency Department Patients With Altered Mental Status

March, 2014

Effect of microEEG® on Clinical Management and Outcomes of Emergency Department Patients With Altered Mental Status: A randomized controlled (RCT). The RCT results of the work up of Emergency Department (ED)/Altered Mental Status (AMS)patients with and without microEEG® have been published in Academic Emergency Medicine Journal (link to full paper). A total of 149 patients were enrolled (76 control and 73 receiving microEEG®). Using microEEG® was associated with change in diagnostic work-up in 49% (95% CI = 38% to 60%) of cases and therapeutic plan in 42% (95% CI = 31% to 53%) of cases immediately after the release of the EEG results. Electroencephalograms (EEGs) obtained by microEEG® can affect diagnostic and therapeutic management of AMS patients in the ED. These findings paired with the high incidence of electroencephalographic abnormalities in AMS patients, further support the need to incorporate EEG in the work-up of these patients in the ED. View Manuscript

microEEG® use by bedside Neonatal ICU (NICU) staff

December, 2013

microEEG® use by bedside Neonatal ICU (NICU) staff: Few NICUs are equipped with EEG machines or staffed with specialized technologists who can properly apply EEG electrodes and provide a technically adequate study. The microEEG® system provided high quality continuous EEG recordings in the NICU performed by bedside staff. This approach was presented at the American Epilepsy Society Annual Meeting- December 2013- Washington D.C. View Presentation

Bio-Signal Group Co. has been selected as one of the 10 winners of PILOT Tech health NYC

June, 2013

Bio-Signal Group Co. has been selected as one of the 10 winners of PILOT Tech health NYC to receive a total of $100K to launch the microEEG® platform in the Emergency Department (ED) of New York Methodist Hospital. This disruptive technology utilizes disposable electrodes and a network of teleneurologists to provide a rapid, remote interpretation of an EEG to an ED physician. Incorporating this technology in the workup of ED patients with neurological emergencies has the potential to make a strong positive impact on the healthcare ecosystem by improving patient care and reducing costs. View More

The Story Collider features a podcast by Dr. André Fenton

March, 2013

The Story Collider features a podcast by Dr. André Fenton: “The twisting road from basic brain research to helping malaria patients. View More

The microEEG® system will be used to assess the effects of tDCS

January, 2013

The microEEG® system will be used to assess the effects of repeated sessions of Transcranial Direct Current Stimulation (tDCS) to the left dorsolateral prefrontal cortex on frequency of interictal discharges and seizure frequency on patients with temporal lobe epilepsy (TLE). The primary behavioral outcomes for this interventional study will be working memory and mood benefit. However, the microEEG® system will help determine if this form of non-invasive neuromodulation can be applied without worsening ictal or interictal activity in TLE patients. The two study sites are at New York University (NYU) Comprehensive Epilepsy Center and the Beth Israel Deaconess Medical Center/Harvard Medical School, Boston MA. The results of this study will have a significant clinical impact for the treatment of the cognitive and psychiatric comorbidities of patients with TLE.

BSG’s poster abstract selected as a “Best Poster”

September, 2012

BSG’s poster abstract on Inter- and Inra-rater reliability in EEG interpretations was selected as a “Best Poster” by the scientific advisory committee of the 10th European Congress on Epileptology in London (September 30th-October 4th 2012). View Poster

BSG receives a 2 year $600K grant award

August, 2012

BSG receives a 2 year $600K grant award from the Eunice Kennedy Shriver National Institute of Child Health & Human Development to conduct clinical trials of its microEEG® System in neonatal ICUs. The trials will be conducted at the State University of New York/Downstate Medical Center/University Hospital of Brooklyn, the Brookdale University Hospital and Medical Center, and the Long Island College Hospital. Project Title: Wireless Novel MicroEEG for Neonatal Apnea and Community Neurological Network.

Dr. Jan Bureš, a great neuroscientist and longtime friend to the BSG family passes away

August, 2012

We wanted to mark the sad news of the passing of Dr. Jan Bureš, a great neuroscientist and longtime friend to the BSG family. We’ve attached an obituary of Dr. Bureš for download here, where you can read about this extraordinary individual. Our deepest condolences to the Bureš family.
– CEO John Gridley